517 related articles for article (PubMed ID: 26154128)
1. Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients.
Sausen M; Phallen J; Adleff V; Jones S; Leary RJ; Barrett MT; Anagnostou V; Parpart-Li S; Murphy D; Kay Li Q; Hruban CA; Scharpf R; White JR; O'Dwyer PJ; Allen PJ; Eshleman JR; Thompson CB; Klimstra DS; Linehan DC; Maitra A; Hruban RH; Diaz LA; Von Hoff DD; Johansen JS; Drebin JA; Velculescu VE
Nat Commun; 2015 Jul; 6():7686. PubMed ID: 26154128
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic value of CA19.9, circulating tumour DNA and circulating tumour cells in patients with solid pancreatic tumours.
Sefrioui D; Blanchard F; Toure E; Basile P; Beaussire L; Dolfus C; Perdrix A; Paresy M; Antonietti M; Iwanicki-Caron I; Alhameedi R; Lecleire S; Gangloff A; Schwarz L; Clatot F; Tuech JJ; Frébourg T; Jardin F; Sabourin JC; Sarafan-Vasseur N; Michel P; Di Fiore F
Br J Cancer; 2017 Sep; 117(7):1017-1025. PubMed ID: 28772284
[TBL] [Abstract][Full Text] [Related]
3. Plasma Circulating Tumor DNA in Pancreatic Cancer Patients Is a Prognostic Marker.
Pietrasz D; Pécuchet N; Garlan F; Didelot A; Dubreuil O; Doat S; Imbert-Bismut F; Karoui M; Vaillant JC; Taly V; Laurent-Puig P; Bachet JB
Clin Cancer Res; 2017 Jan; 23(1):116-123. PubMed ID: 27993964
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of circulating tumour DNA in patients undergoing curative resection for pancreatic cancer.
Hadano N; Murakami Y; Uemura K; Hashimoto Y; Kondo N; Nakagawa N; Sueda T; Hiyama E
Br J Cancer; 2016 Jun; 115(1):59-65. PubMed ID: 27280632
[TBL] [Abstract][Full Text] [Related]
5. Analysis of ctDNA to predict prognosis and monitor treatment responses in metastatic pancreatic cancer patients.
Cheng H; Liu C; Jiang J; Luo G; Lu Y; Jin K; Guo M; Zhang Z; Xu J; Liu L; Ni Q; Yu X
Int J Cancer; 2017 May; 140(10):2344-2350. PubMed ID: 28205231
[TBL] [Abstract][Full Text] [Related]
6. Pancreatic cancer: Are "liquid biopsies" ready for prime-time?
Lewis AR; Valle JW; McNamara MG
World J Gastroenterol; 2016 Aug; 22(32):7175-85. PubMed ID: 27621566
[TBL] [Abstract][Full Text] [Related]
7. Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma.
De Mattos-Arruda L; Mayor R; Ng CKY; Weigelt B; Martínez-Ricarte F; Torrejon D; Oliveira M; Arias A; Raventos C; Tang J; Guerini-Rocco E; Martínez-Sáez E; Lois S; Marín O; de la Cruz X; Piscuoglio S; Towers R; Vivancos A; Peg V; Ramon y Cajal S; Carles J; Rodon J; González-Cao M; Tabernero J; Felip E; Sahuquillo J; Berger MF; Cortes J; Reis-Filho JS; Seoane J
Nat Commun; 2015 Nov; 6():8839. PubMed ID: 26554728
[TBL] [Abstract][Full Text] [Related]
8. Circulating tumor DNA as a liquid biopsy target for detection of pancreatic cancer.
Takai E; Yachida S
World J Gastroenterol; 2016 Oct; 22(38):8480-8488. PubMed ID: 27784960
[TBL] [Abstract][Full Text] [Related]
9. Genomic instability in pancreatic adenocarcinoma: a new step towards precision medicine and novel therapeutic approaches.
Sahin IH; Lowery MA; Stadler ZK; Salo-Mullen E; Iacobuzio-Donahue CA; Kelsen DP; O'Reilly EM
Expert Rev Gastroenterol Hepatol; 2016 Aug; 10(8):893-905. PubMed ID: 26881472
[TBL] [Abstract][Full Text] [Related]
10. Circulating mutational portrait of cancer: manifestation of aggressive clonal events in both early and late stages.
Yang M; Topaloglu U; Petty WJ; Pagni M; Foley KL; Grant SC; Robinson M; Bitting RL; Thomas A; Alistar AT; Desnoyers RJ; Goodman M; Albright C; Porosnicu M; Vatca M; Qasem SA; DeYoung B; Kytola V; Nykter M; Chen K; Levine EA; Staren ED; D'Agostino RB; Petro RM; Blackstock W; Powell BL; Abraham E; Pasche B; Zhang W
J Hematol Oncol; 2017 May; 10(1):100. PubMed ID: 28472989
[TBL] [Abstract][Full Text] [Related]
11. Using circulating cell-free DNA to monitor personalized cancer therapy.
Oellerich M; Schütz E; Beck J; Kanzow P; Plowman PN; Weiss GJ; Walson PD
Crit Rev Clin Lab Sci; 2017 May; 54(3):205-218. PubMed ID: 28393575
[TBL] [Abstract][Full Text] [Related]
12. Utility of Genomic Assessment of Blood-Derived Circulating Tumor DNA (ctDNA) in Patients with Advanced Lung Adenocarcinoma.
Schwaederlé MC; Patel SP; Husain H; Ikeda M; Lanman RB; Banks KC; Talasaz A; Bazhenova L; Kurzrock R
Clin Cancer Res; 2017 Sep; 23(17):5101-5111. PubMed ID: 28539465
[No Abstract] [Full Text] [Related]
13. [What future for circulating tumor DNA? Current data and prospects in colorectal, non-small cell lung and pancreatic cancers].
Pietrasz D; Pécuchet N; Fabre E; Blons H; Chevalier L; Taly V; Laurent-Puig P; Bachet JB
Bull Cancer; 2016 Jan; 103(1):55-65. PubMed ID: 26790710
[TBL] [Abstract][Full Text] [Related]
14. Personalized Circulating Tumor DNA Biomarkers Dynamically Predict Treatment Response and Survival In Gynecologic Cancers.
Pereira E; Camacho-Vanegas O; Anand S; Sebra R; Catalina Camacho S; Garnar-Wortzel L; Nair N; Moshier E; Wooten M; Uzilov A; Chen R; Prasad-Hayes M; Zakashansky K; Beddoe AM; Schadt E; Dottino P; Martignetti JA
PLoS One; 2015; 10(12):e0145754. PubMed ID: 26717006
[TBL] [Abstract][Full Text] [Related]
15. Detection of K-ras gene mutation by liquid biopsy in patients with pancreatic cancer.
Kinugasa H; Nouso K; Miyahara K; Morimoto Y; Dohi C; Tsutsumi K; Kato H; Matsubara T; Okada H; Yamamoto K
Cancer; 2015 Jul; 121(13):2271-80. PubMed ID: 25823825
[TBL] [Abstract][Full Text] [Related]
16. Diagnosis of pancreatico-biliary malignancy: detection of gene mutations in plasma and stool.
Mulcahy H; Farthing MJ
Ann Oncol; 1999; 10 Suppl 4():114-7. PubMed ID: 10436800
[TBL] [Abstract][Full Text] [Related]
17. Clinical Implications of Monitoring Circulating Tumor DNA in Patients with Colorectal Cancer.
Schøler LV; Reinert T; Ørntoft MW; Kassentoft CG; Árnadóttir SS; Vang S; Nordentoft I; Knudsen M; Lamy P; Andreasen D; Mortensen FV; Knudsen AR; Stribolt K; Sivesgaard K; Mouritzen P; Nielsen HJ; Laurberg S; Ørntoft TF; Andersen CL
Clin Cancer Res; 2017 Sep; 23(18):5437-5445. PubMed ID: 28600478
[No Abstract] [Full Text] [Related]
18. Clinical value of ctDNA in upper-GI cancers: A systematic review and meta-analysis.
Creemers A; Krausz S; Strijker M; van der Wel MJ; Soer EC; Reinten RJ; Besselink MG; Wilmink JW; van de Vijver MJ; van Noesel CJM; Verheij J; Meijer SL; Dijk F; Bijlsma MF; van Oijen MGH; van Laarhoven HWM
Biochim Biophys Acta Rev Cancer; 2017 Dec; 1868(2):394-403. PubMed ID: 28801248
[TBL] [Abstract][Full Text] [Related]
19. Circulating Tumor DNA as a Sensitive Marker in Patients Undergoing Irreversible Electroporation for Pancreatic Cancer.
Lin M; Alnaggar M; Liang S; Chen J; Xu K; Dong S; Du D; Niu L
Cell Physiol Biochem; 2018; 47(4):1556-1564. PubMed ID: 29940591
[TBL] [Abstract][Full Text] [Related]
20. Very early response of circulating tumour-derived DNA in plasma predicts efficacy of nivolumab treatment in patients with non-small cell lung cancer.
Iijima Y; Hirotsu Y; Amemiya K; Ooka Y; Mochizuki H; Oyama T; Nakagomi T; Uchida Y; Kobayashi Y; Tsutsui T; Kakizaki Y; Goto T; Miyashita Y; Omata M
Eur J Cancer; 2017 Nov; 86():349-357. PubMed ID: 29078173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
